Primary Site >> Biliary tract Cancer

Gene >> MAP2K1

  • 2006
  • 2007
  • 2011
  • 2014
  • 2016
  • 2017
  • 2018
Ref: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
PMID: 16525641
Ref: Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats.
PMID: 16601979
Ref: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
PMID: 16950403
 Ref: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
PMID: 17461449
 Ref: Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.
PMID: 21910575
 Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
PMID: 24889489
 Ref: Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
PMID: 26683364
Ref: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
PMID: 26912134
 Ref: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
PMID: 27811010
Ref: Blocking ERK1/2 signaling impairs TGF-beta1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells.
PMID: 28959141
 Ref: Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
PMID: 29121415
Ref: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
PMID: 29785570